SNOA
NASDAQ · Pharmaceuticals
Sonoma Pharmaceuticals Inc
$1.26
+0.01 (+0.80%)
Financial Highlights (FY 2026)
Revenue
54.66M
Net Income
-8,887,033
Gross Margin
38.0%
Profit Margin
-16.3%
Rev Growth
+13.8%
D/E Ratio
0.07
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 38.0% | 38.0% | 35.0% | 35.0% |
| Operating Margin | -12.6% | -11.3% | 23.2% | 24.4% |
| Profit Margin | -16.3% | -15.5% | 25.4% | 21.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 54.66M | 48.06M | 1.82M | 1.63M |
| Gross Profit | 20.76M | 18.25M | 638.4K | 569.1K |
| Operating Income | -6,887,506 | -5,449,455 | 423.5K | 396.5K |
| Net Income | -8,887,033 | -7,031,498 | 463.1K | 348.9K |
| Gross Margin | 38.0% | 38.0% | 35.0% | 35.0% |
| Operating Margin | -12.6% | -11.3% | 23.2% | 24.4% |
| Profit Margin | -16.3% | -15.5% | 25.4% | 21.5% |
| Rev Growth | +13.8% | +13.8% | -7.1% | +16.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 201.8K | 201.8K | 821.0K | 810.3K |
| Total Equity | 2.81M | 2.81M | 2.76M | 3.02M |
| D/E Ratio | 0.07 | 0.07 | 0.30 | 0.27 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -6,499,591 | -5,428,229 | 609.2K | 511.6K |
| Free Cash Flow | — | — | 381.4K | 338.4K |